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 The eNOS pathway, found in the endothelium of blood vessels, is a key regulator of  
nitric oxide levels in the circulatory system. The pathway is controlled through several positive  
and negative feedback loops [2]. The cofactor tetrahydrobiopterin (BH4) is a major control point 
in this pathway and under conditions of stress can be reduced into the dihydrobiopterin (BH2) 
[2,6,7,8,9]. When the reduced form is predominant, the pathway produces reactive oxygen 
species (ROS) rather than nitric oxide, causing stress and damage to the vessels [6,7,8,9]. In this 
study, different treatments were studied to determine which is most effective in restoring BH4 
levels in the eNOS pathway of bovine aortic endothelial cells (BAECs). Nitric oxide 
supplementation was the main focus of this study and was tested as a stand-alone treatment and 
as a combined treatment along with a BH4 donor drug, sapropterin dihydrochloride. Following 
the two treatments, only the BAECs given the nitric oxide donor drug showed levels of BH4 
higher than the untreated control cells. The cells treated with 25 M nitric oxide donor drug and 
2.5 M BH4 donor drug showed levels of BH4 that were most similar to the untreated control 
cells with a concentration of approximately 27 mM BH4.  
Introduction 
 According to the American Heart Association, in 2016, nearly 1 in every 3 deaths can be  
attributed to some form of cardiac dysfunction, making it a prime area of interest for researchers  
[1]. In recent years, nitric oxide (NO) deficiency has been identified as a key player in cardiac  
dysfunction [2]. NO acts as a neurotransmitter and promotes vasodilation, electrical  
stimulation of the pacemaker, and angiogenesis [3,4,5]. Deficiency of NO in the blood vessel 
endothelium can be largely attributed to uncoupling of the enodothelial nitric oxide synthase 
(eNOS) pathway [6,7]. The eNOS pathway converts L-arginine to L-citrulline and NO using the 
cofactor tetrahydrobiopterin (BH4) [2,6,7,8,9]. When the eNOS pathway is uncoupled, levels of 
L-arginine, L-citrulline, and BH4 are reduced, and the O2
- radical is produced [8]. As radical 
species accumulate in the blood vessel endothelium, NO is scavenged by the uncoupled eNOS to 
produce peroxynitrite (ONOO.) [8]. High levels of ONOO. create further oxidative stress, leading 
to a cascade of cardiac stress [8]. One induction of oxidative stress can cause this cascade to be 
initiated, leading to low bioavailability of NO in the blood vessels and high concentrations of 
superoxide radicals [10]. A method to mediate this oxidative stress cascade in cardiac arrest 
cases is to supplement NO by inhalation or medication [11,12].  
           Cardiac arrest has been identified as a significant cause of oxidative stress in the blood 
vessel endothelium [8,11,12]. Therefore, in cases where NO supplementation was used as a 
treatment after cardiac arrest, many of the eNOS pathways may have been uncoupled due to 
ischemia beginning the cardiac cascade [8,11,12]. Uncoupling of the eNOS is not isolated to 
cardiac arrest and is associated with atherosclerosis, diabetes mellitus, ischemia-reperfusion (I/R) 
injury, hypertension, chronic flow overload, cardiac hypertrophy with ventricular remodeling, 
and diastolic heart failure [8]. New therapies have emerged which introduce BH4 into the blood 
vessel endothelium to recouple the eNOS pathways and upregulate NO synthesis [7]. Other 
studies have also expressed issues with NO introduction because of the instability of the gas and 
its disruption of hemoglobin function [13]. If BH4 therapy recouples eNOS pathways in a time 
efficient manner, it could prove to be a more suitable and efficient therapy for patients following 
cardiac arrest that need NO supplementation. This researcher proposes a combined therapy for 
optimal results where BH4 is introduced to shift the eNOS pathways into the correct position, 
followed with NO. It is possible that the combined treatments will allow nitric oxide levels to be 
increased to proper levels for a longer period of time than seen in previous studies. 
          In this study, bovine aortic endothelial cells (BAECs) were cultured and then introduced to 
oxidative stress in order to uncouple the eNOS pathway. An assay of biopterin was conducted 
using High Performance Liquid Chromatography (HPLC) to determine if the oxidized (BH4) or 
reduced form (BH2) of biopterin was present, which indicated the coupled and uncoupled forms 
of the eNOS pathway, respectively. Nitric oxide donor drugs were given to the BAECs following 
oxidative stress, to see if BH4 levels increased in the cells favoring the coupled conformation of 
the eNOS pathway. A combined treatment of sapropterin dihydrochloride and nitric oxide donor 
drugs were also given to the BAECs to determine if this is more effective in restoring the 
oxidized form of biopterin in the cell samples. This researcher hypothesized that BAECs given 
the combined treatment would produce higher levels of BH4 than the nitric oxide donor drugs 
alone.  
Methods  
Cell Culture  
         Bovine aortic endothelial cells were obtained through the Coriell Institute and incubated 
overnight as directed by the provider before being transferred to a T-75 culture flask using 
aseptic technique. BAECs were grown in Eagle’s Minimum Essential Media (EMEM) that was 
supplemented with 10% fetal bovine serum (FBS) until early confluency. At 80% confluency, 
cells were sub-cultured using Trypsin/EDTA as the dissociation solution. The cells were spun 
down at 180 x g for 5 minutes and the supernatant was removed without disturbing the cell 
pellet. The cell pellet was resuspended in 2 to 8 mL of growth medium by pipetting gently up 
and down. Before further processing, 100 L of cell suspension was removed for counting on the 
hemocytometer.  Cells were then seeded at a density of 2,500 to 5,000 cells per cubic centimeter. 
Flasks were placed in an incubator set at 37 degrees Celsius and 5% CO2 for at least 24 hrs 
before the cells were further processed. Growth media was changed every 48 hrs between 
subculturing or when the media showed a significant pH change. All culturing was performed 
using aseptic technique in a laminar flow hood with a HEPA filter. Human embryonic kidney 
(HEK293) cells were used as a control cell type and were sourced from frozen stocks provided 
by Olivet Nazarene University’s Biology Department. The HEK293 cells were cultured using the 
same protocol as described for the bovine aortic endothelial cells.  
Induction of Oxidative Stress 
         Each cell type was plated on a 12-well plate and cytotoxicity treatments were done in 
triplicate using a serial dilution of hydrogen peroxide (H2O2) concentrations (200 M, 100 M, 
50 M and 25 M). Results from the cytotoxicity tests were used to determine the concentration 
of H2O2 to be used for oxidative stress induction. Cells were seeded on 12-well plates and were 
treated at early confluence with 100 L of 100 M of H2O2 dissolved in 1X D-PBS to induce 
oxidative stress. Cells were incubated with the treatment for 24 hours before the media was 
removed by aspiration and replaced with serum-free media or treatment media.  
NO and BH4 supplementation 
              BAECs and HEK293 cells were treated in triplicate with several concentrations of 
diethylamine NONOate diethylammonium salt, a slow releasing NO donor drug. This was done 
using a serial dilution method to give final concentrations of 25, 50, 100 and 200 M. Cell 
viability counts, a nitrite assay, and HPLC analysis were completed to determine the 
approximate LD50 of the NO donor drug. The optimum concentration was determined to be at or 
below 100 M of diethylamine NONOate diethylammonium salt. For the combined treatments, 
lower concentrations of NO donor drug were used to offset the additional treatment given to the 
cells. Sapropterin dihydrochloride, a precursor of BH4, was used as the BH4 donor drug in the 
combined treatment. Low concentrations of this drug were used due to lack of information about 
approximate cellular concentrations and toxicity found in the literature. Concentrations of 2.5 
and 1.25 M of BH4 donor drug were given to the cells in triplicate in combination with 25 and 
12.5 M of nitric oxide donor drug, respectively. Cells were incubated with these treatments for 
12 hours before being collected for HPLC analysis.  
HPLC Quantification of BH4 and BH2 
          An isocratic method was used for quantification of BH2 and BH4 using the Hitachi Elite 
LaChrom HPLC. A four-point standard curve was created using (6R)-5,6,7,8-tetrahydrobiopterin 
dihydrochloride, a BH4 supplement drug, that had been incubated for an hour in the dark with an 
alkaline (0.02 M KI/I2 in 0.1 M NaOH, for detection of BH2) or an acidic (0.02 M KI/I2 in 0.1 M 
HCl, for detection of BH2 and BH4) solution. The oxidized alkaline or acidic samples were 
mixed with 10 L 1M HCl or water (respectively) and centrifuged to retrieve supernatants. The 
supernatants were then mixed with 10 L 0.2 M ascorbic acid and neutralized with 1 M 
phosphate buffer with pH 8. The final sample was filtered and 30 L was injected into the HPLC 
and detection was run at = 350 nm and = 450 nm. This method was repeated using cell 
suspensions collected from the 12-well plates following oxidative stress and after nitric oxide 
and tetrahydrobiopterin supplementation. The alkaline area beneath the curve was subtracted 
from the acidic area for each treatment to determine the concentration of BH4 in each sample.  
Results  
           In Figure 1, the standard curve made using known concentrations of BH4 is shown. This 
curve was used for later determination of BH4 concentration in the BAECs and HEK293 
samples and for indication of the coupled and uncoupled conformation of the eNOS pathway in 
the cell samples before and after the induction of oxidative stress. 
 
Figure 1.  Standard curve of BH4 concentrations  
 
            Figure 2 shows the multichromatogram of a control BAEC sample run prior to the 
induction of oxidative stress. The sample was run incubated with the alkaline condition before 
being run on the HPLC. The alkaline area was subtracted from the acidic area to give the 
baseline concentration of BH4 in the BAECs. Several runs of control cell samples were 
compared with the standard curve multichromatograms to confirm that the double peak seen 
between two and three minutes of elution shows the elution of BH4 from the column. This 
double peak was used to calculate the area beneath the curve for the calculation of BH4 



















































Figure 2. Multichromatogram of BAECs without oxidative stress run with alkaline conditions 
 
      
         Figure 3 shows the multichromatogram of a representative sample of BAECs that were 
treated with 100 M H2O2 to induce oxidative stress. The BH4 concentration found in these 
samples was used to show that oxidative stress had converted the BH4 form of biopterin to the 




Figure 3. Multichromatogram of BAECs with 100 M H2O2 run with the alkaline condition* 
*Note that the range presented on vertical axis of each multichromatogram varies from sample to sample due to the 
figures being taken directly from the instrument.  
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with nitric oxide donor drugs is shown under alkaline conditions. In this multichromatogram, the 
solvent peak (peak at approximately one minute of elution), is larger than the double peak. In 
Figures 2 and 3, the solvent peak was smaller than the BH4 peak by a considerable amount. 
Another variance in Figure 4 compared to the previous multichromatograms is that the first peak 




Figure 4. Multichromatogram of BAECs treated with 100 M H2O2 and 100 M NO donor drug 
under alkaline conditions. 
 
         In Figure 5, the cells given the combined treatment of 25 M nitric oxide donor drug and  
 
2.5 M BH4 donor drug is shown under alkaline conditions. This multichromatogram shows a  
 
larger BH4 peak than seen in Figure 4, but the same inversion of the double peak in comparison  
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Figure 5. Multichromatogram of BAECs treated with 100 M H2O2 and 25 M NO donor drug 
and 2.5 M BH4 donor drug under alkaline conditions. 
 
         In Figure 6, BH4 concentration is plotted for each treatment, conducted in triplicate and 
averaged. Standard deviations are also plotted for each of the treatments. The negative control 
received no treatment while the positive control underwent oxidative stress induced by 100 M 
H2O2. The BH4 concentration of approximately 22 mM was considered the target concentration 
for BH4 restoration and was found as an average of three wells of untreated BAECs. A BH4 
concentration of approximately 12 mM was considered to be uncoupled and was found as the 
average of three wells of BAECs cells following oxidative stress with 100 M of H2O2. 
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             Each concentration of nitric oxide donor drug alone resulted in a BH4 concentration of 
approximately 33 mM. The combined treatment of 12.5 M nitric oxide and 1.25 M BH4 donor 
drugs had a concentration of BH4 of approximately 12 mM. The higher concentration of 
combined treatment, 25 M nitric oxide and 2.5 M BH4 donor drugs, lead to a BH4 
concentration of approximately 27 mM. 
Discussion  
        The BAECs given the combined treatment of 25 M nitric oxide and 2.5 M BH4 donor 
drugs exhibited a BH4 concentration that was the closest to the untreated BAECs. However, the 
BAECs treated with only the nitric oxide donor drug showed the highest concentration of BH4 at 
a concentration of approximately 33 mM. The combined treatment of 12.5 M nitric oxide and 
1.25 M BH4 was less effective than the higher concentration at increasing BH4 concentration. 
This treatment, when analyzed with the HPLC, indicated a concentration that was nearly the 
same as in the BAECs after undergoing oxidative stress. This suggests that there may be a 
threshold in which the sapropterin dihydrochloride becomes effective that is between a 2.5 M to 
1.25 M. A greater range of concentrations should be tested to determine if this is the cause of 
the low concentration of BH4 in the BAECs given the combined treatment. Continued testing of 
a greater range of combined treatments would also help to determine if the sapropterin 
dihydrochloride works synergistically with the diethylamine NONOate diethylammonium salt to 
raise BH4 concentrations.  
        Previous studies have not defined a normal range of intracellular concentration for BH4, a 
circumstance that makes data interpretation difficult for this experiment. However, it has been 
suggested that a higher bioavailability of BH4 promotes angiogenesis and nitric oxide production 
and has not been found to have negative effects in high abundance [24]. This suggests that the 
treatment of nitric oxide alone may be more effective than the combined treatment for the range 
of concentrations tested in this study. Another possibility is that while increased BH4 
concentration is not harmful, it does reach a saturated level. At this point, it is no longer as able 
to be utilized by the cell. If this prediction is accurate, it may mean that the nitric oxide donor 
drug and the combined treatment of 25 M nitric oxide and 2.5 M BH4 donor drug are equally 
effective at restoring BH4 levels in the BAECs.  
          Another discrepancy in the data is seen when comparing the multichromatograms for the 
positive and negative control cell samples seen in Figures 2 and 3 and the cells given both 
treatments shown in Figures 4 and 5. The double peak seen between two and three minutes of 
elution changes in shape after the cells were given treatments. The first of the BH4 double peaks 
is larger in the samples analyzed after treatment. An explanation for this could be that the 
treatment elutes near the time expected for the BH4 to elute, causing the first peak to have a 
greater area than in the positive and negative control cells. Also, the double peak used to 
calculate BH4 concentration may not only include BH4. In order to calculate BH4 concentration, 
the area beneath the entire double peak was measured, and this could have led to considerable 
error in the calculations. The protocol for the acidic and alkaline preparations of the cell samples 
may also have led to error in the HPLC analysis. The protocol required many steps and reagents 
with short shelf-lives. These circumstances may have contributed to experimental error.  
       Because of the lack of clarity in these results, the hypothesis could not be supported. 
Additional studies should be conducted to assay other control points within the eNOS pathway to 
determine which treatment is more effective at restoring the coupled conformation of the 
pathway. Nitrite assays would be helpful in determining the effectiveness of each treatment.  
 
Conclusion 
         The data collected in this experiment was not sufficient to support the effectiveness of 
either of the treatments in comparison to the other. The nitric oxide donor drug treatments 
yielded a concentration of 33 mM BH4 while the combined treatment of 25 M nitric oxide and 
2.5 M BH4 donor drugs raised the BH4 concentration to approximately 27 mM. Each treatment 
type was sufficient at raising the concentration of BH4 in the cells to levels at or above those 
seen in the control BAECs. However, without data from additional assays for reactive oxygen 
species or angiogenesis rates, a conclusion cannot be made as to which treatment is more 
effective for recoupling the eNOS pathway. 
                Additionally, the data among the BAECs given the combined treatment was not 
consistent, suggesting that the optimal concentration of BH4 donor drug was likely not used in 
each of the treatments. Cytotoxicity studies should be done in greater depth before further 
experiments are conducted. The scope of this experiment also did not allow for the possible 
synergistic effects of the combined treatment to be evaluated. Modifications to the HPLC 
methodology in previous experiments may have led to inaccuracies in the integration of the area 
beneath each peak, leading to errors in the calculation of BH4 concentration. In future 
experiments, the method for the acidic and alkaline preparation of the cells and the HPLC 
protocol should be simplified to reduce potential error.   
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